Drug Trial Radar · NCT06425341
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
369
Planned (sponsor's estimate)
Start
Jun 6, 2024
Primary completion
Aug 30, 2026
Study completion Jan 19, 2027
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.
Conditions
- Chronic Hepatitis B
Interventions
HRS-5635 InjectionDrug
HRS-5635 Injection low dose administered by subcutaneous injection
HRS-5635 InjectionDrug
HRS-5635 Injection medium dose administered by subcutaneous injection
HRS-5635 InjectionDrug
HRS-5635 Injection high dose administered by subcutaneous injection
HRS-5635 InjectionDrug
HRS-5635 Injection lowest dose administered by subcutaneous injection
HRS-5635 Injection (low dose) and Peg-IFN-αDrug
HRS-5635 Injection (low dose) and Peg-IFN-α, administered by subcutaneous injection
HRS-5635 Injection (high dose) and Peg-IFN-αDrug
HRS-5635 Injection (high dose) and Peg-IFN-α, administered by subcutaneous injection
Peg-IFN-αDrug
Peg-IFN-α, administered by subcutaneous injection
HRS-5635 Injection with Peg-IFN-αDrug
HRS-5635 Injection and Peg-IFN-α, administered by subcutaneous injection
HRS-5635 InjectionDrug
HRS-5635 Injection, administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- PartA:Change in mean log10 serum hepatitis B surface antigen levels from baseline at week 12Time frame: Week 12
- PartB:Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48Time frame: Week 48
- PartC:Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48Time frame: Week 48
- PartD:Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48Time frame: Week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanfang Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.